Compare iShares MSCI Japan ETF (EWJ) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Japan ETF vs Organon & Co. Common Stock — how do they compare? iShares MSCI Japan ETF trades at $94.77 (market cap $23.55B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: iShares MSCI Japan ETF is far larger — about 6.5× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while iShares MSCI Japan ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Japan ETF for 57 Days and Organon & Co. Common Stock for 0 Days on average.
| EWJ | OGN | |
|---|---|---|
Market Cap | $23.55B | $3.62B |
Volume | 1,896,806 | 2,892,999 |
Sector | Broad Market / Factor | Health |
52-Week High | $99.32 | $13.81 |
52-Week Low | $79.49 | $5.70 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $97.32 with no significant daily movement. Technical indicators show a bullish overall signal with moving averages supporting upward momentum, while oscillators remain neutral. The ETF benefits from Japan's economic developments including recent Bank of Japan rate hikes and fiscal stimulus measures. Support and resistance levels cluster tightly around the current price, indicating potential for breakout movement.
The outlook for EWJ appears cautiously optimistic as Japan navigates monetary policy normalization while maintaining growth stimulus. Investment opportunities include exposure to Japan's AI and semiconductor sectors, though risks persist from yen volatility, rising bond yields, and global macroeconomic pressures. The ETF's performance relative to the S&P 500 in 2026 suggests international diversification benefits.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
